Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas

Histopathology

Volumn 47, Issue 3, 2005, Pages 281-291

  Paik, J H ^a   Jeon, Y K ^a   Park, S S ^a   Kim, Y A ^b   Kim, J E ^b   Huh, J ^c   Lee, S S ^d   Kim, W H ^a   Kim, Chul Woo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Asan Medical Center   (South Korea)

^d Korea Cancer Centre Hospital   (South Korea)

Author keywords

Diffuse large B cell lymphoma; p14 ARF; p16 INK4a; p53; Tissue microarray

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; PROTEIN BCL 6; PROTEIN P14; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CELL CYCLE; CONTROLLED STUDY; FEMALE; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; SURVIVAL; TISSUE MICROARRAY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; CHILD; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GERMINAL CENTER; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 24144456978     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02222.x     Document Type: Article

References (32)

1. Gatter KC, Warnke RA. Diffuse large B cell lymphoma. In Jaffe ES, Harris NL, Stein H, Vardiman JW eds. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press 2001; 171-176.
2. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89; 3909-3918.
3. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103; 275-82.
4. Barrans SL, Carter I, Owen RG et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99; 1136-1143.
5. The international Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 329; 987-994.
6. Engelhard M, Brittinger G, Huhn D et al. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood 1997; 89; 2291-2297.
7. Baars JW, de Jong D, Willemse EM et al. Diffuse large B-cell non-Hodgkin lymphomas: the clinical relevance of histological subclassification. Br. J. Cancer 1999; 79; 1770-1776.
8. Diebold J, Anderson JR, Armitage JO et al. Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk. Lymphoma 2002; 43; 97-104.
9. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403; 503-511.
10. Zettl A, Meister S, Katzenberger T et al. Immunohistochemical analysis of B-cell lymphoma using tissue microarrays identifies particular phenotypic profiles of B-cell lymphomas. Histopathology 2003; 43; 209-219.
11. Colomo L, Lopez-Guillermo A, Perales M et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101; 78-84.
12. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 2002; 8; 68-74.
13. Rosenwald A, Wright G, Chan WC et al.: Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl J. Med. 2002; 346; 1937-1947.
14. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood 2003; 101; 1220-1235.
15. Bai M, Vlachonikolis J, Agnantis NJ et al. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas. Mod. Pathol. 2001; 14; 1105-1113.
16. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P, eds. Molecular biology of the cell 4th edn. New York: Garland 2002; 990-997.
17. Takimoto R, El-Deiry WS. DNA replication blockade impairs p53-transactivation. Proc. Natl Acad. Sci. USA 2001; 98; 781-783.
18. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 1998; 4; 844-847.
19. Nocito A, Kononen J, Kallioniemi OP et al. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int. J. Cancer 2001; 94; 1-5.
20. Garcia JF, Camacho FI, Morente M et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003; 101; 681-689.
21. Elenitoba-Johnson KS, Gascoyne RD, Lim MS et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998; 91; 4677-4685.
22. Pruneri G, Carboni N, Baldini L et al. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation. Hum. Pathol. 2003; 34; 41-47.
23. Nakamura M, Sakaki T, Hashimoto H et al. Frequent alterations of the p14 (ARF) and p16 (INK4a) genes in primary central nervous system lymphomas. Cancer Res. 2001; 61; 6335-6339.
24. Uherova P, Ross CW, Schnitzer B, Singleton TP, Finn WG. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. Am. J. Clin. Pathol. 2001; 115; 582-588.
25. Chang CC, Cleveland RP, Perkins SL. CD10 expression and survival. Am. J. Clin. Pathol. 2002; 117; 660-661.
26. Takeshita M, Iwashita A, Kurihara K et al. Histologic and immunohistologic findings and prognosis of 40 cases of gastric large B-cell lymphoma. Am. J. Surg. Pathol. 2000; 24; 1641-1649.
27. Losses IS, Jones CD, Warnke R et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001; 98; 945-951.
28. Falini B, Fizzotti M, Pucciarini A et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95; 2084-2092.
29. Gronbaek K, de Nully Brown P, Moller MB et al. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia 2000; 14; 1727-1735.
30. Villuendas R, Pezzella F, Gatter K et al. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21- immunophenotype associated with missense p53 mutations. J. Pathol. 1997; 181; 51-61.
31. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 1998; 92; 770-777.
32. Moller MB, Skjodt K, Mortensen LS, Pedersen NT. Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27Kip1. Br. J. Haematol. 1999; 105; 730-736.